A
Arovella Therapeutics
ALA
Last Price
52 Week Range
A$0.07 - A$0.13
Next Earnings Date
Sep 02 2026 (Estimate)
Next Earnings Date
Sep 02 2026 (Est.)
Last Price
Arovella Therapeutics Investor Relations
Arovella Therapeutics Earnings Call Summary
Arovella Therapeutics Earnings
Estimates
Actual
Y-on-Y Change
Revenue
EPS
Transcripts
Events
About Arovella Therapeutics Limited
A
Arovella Therapeutics Limited
ALA
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that...
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Sector
Industry
CEO
Baker, Michael
Employees
27
Website
www.arovella.comIPO Date
Headquarters
Corporate One, 84 Hotham Road, Preston, Victoria, 3072, Australia
Gainify
Features
Platform
Resources
Learn
Socials
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
© 2026 Gainify. All rights reserved.